Y's Therapeutics, Inc. Completes Enrollment of Phase II Trial in the U.S. With YSPSL for Prevention of Delayed Graft Function in Renal Transplantation

Published: Apr 24, 2007

TOKYO -- (MARKET WIRE) -- April 24, 2007 -- Y's Therapeutics, a privately held biopharmaceutical company, announced the completion of patient enrollment for its Phase II clinical trial of YSPSL for prevention of delayed graft function (DGF) in kidney transplant patients. The clinical trial enrolled 75 patients across 15 leading US transplant centers to evaluate the safety and efficacy of YSPSL (r-PSGL-Ig, recombinant P-selectin glycoprotein immunoglobulin) for prevention of DGF in patients undergoing cadaveric kidney transplantation.

Back to news